TrialThe Lancet. Neurology2023

Safety and efficacy of propranolol for treatment of familial cerebral cavernous malformations (Treat_CCM): a randomised, open-label, blinded-endpoint, phase 2 pilot trial.

Silvia Lanfranconi et al.PubMed ↗Publisher ↗

No numbers read from the abstract.